3D Medicines Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From 3D Medicines Inc.
ImmuneOncia CEO talks to Scrip about the development strategy for its anti-PD-L1 and anti-CD47 pipeline assets as well as the advantages of having Yuhan and Sorrento as its largest shareholders.
Multinationals including AstraZeneca are retreating from China’s overcrowded immuno-oncology market but one exception - Pfizer - remains steadfast.
The latest immuno-oncology newcomers from Lee’s Pharma and Jiangsu Hengrui will further choke an already crowded field in China if they are approved following recent filings.
PD-1 Inhibitor Market Poised For A New Round Of Expansion: After GSK’s Jemperli Approval, US FDA Still Has Three Novel Candidates Under Review
Agenus’ recent submission of balstilimab joins novel checkpoint inhibitors from Incyte expecting FDA action this year; Junshi and Coherus’ ongoing rolling BLA for toripalimab is the first from the multiple PD-1/L1 inhibitor candidates developed in China that are vying to enter the US market.
- Other Names / Subsidiaries
- 3D Medicines (Sichuan) Co., Ltd.
- 3D Medicines (Beijing) Co., Ltd.